Market Research Logo

Singapore Pharmaceuticals and Healthcare Report Q2 2016

Singapore Pharmaceuticals and Healthcare Report Q2 2016

BMI View: Non-communicable disease will continue to dominate Singapore's epidemiological profile,creating strong commercial opportunities for medicines addressing these illnesses. Companies seeking tobenefit from these revenue earning prospects will have to compete with the population's ongoing use ofalternative treatments as a supplement to conventional medicine.

Headline Expenditure Projections

Pharmaceuticals: SGD1.10bn (USD798mn) in 2015 to SGD1.15bn (USD790mn) by 2016; +5.1% inlocal currency terms and -0.9% in USD terms.

Healthcare: SGD19.67bn (USD14.31bn) in 2015 to SGD21.15bn (USD14.50bn) by 2016; +7.5% inlocal currency terms and 1.3% in USD terms.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2014-2020)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020)
Industry Risk/Reward Index
Asia Pacific Risk/Reward Index
Singapore Risk/Reward Index
Rewards
Risks
Regulatory Review
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA
Intellectual Property Issues
Pricing And Reimbursement Regime
Market Overview
Healthcare Sector
Table: Health Funding Sources In Singapore (SGDmn)
Table: Healthcare Resources (Singapore 2010-2015)
Table: Healthcare Activity (Singapore 2010-2015)
Table: Healthcare Personnel (Singapore 2010-2015)
Research & Development
Clinical Trials
Epidemiology
Table: Estimated Number Of New Cases Of Cancer In Singapore
Competitive Landscape
Research-Based Industry
Table: Multinational Pharmaceutical Firm Presence In Singapore
Table: Multinational Market Activity
Table: Leading Generic Drugmakers In Singapore
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
Baxter
GlaxoSmithKline
Haw Par
Merck & Co
MerLion
Novartis
Pfizer
Sanofi
Sci Gen
Demographic Forecast
Demographic Outlook
Table: Population Headline Indicators (Singapore 1990-2025)
Table: Key Population Ratios (Singapore 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025)
Table: Population By Age Group (Singapore 1990-2025)
Table: Population By Age Group % (Singapore 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report